- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: STAT3.
Displaying page 1 of 1.
EudraCT Number: 2017-005057-36 | Sponsor Protocol Number: GLG-801-07 | Start Date*: 2018-05-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GLG Pharma S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002909-25 | Sponsor Protocol Number: 74310 | Start Date*: 2020-10-21 |
Sponsor Name:Amsterdam University Medical Centers | ||
Full Title: Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study | ||
Medical condition: oesophageal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019937-85 | Sponsor Protocol Number: dmestatina | Start Date*: 2010-09-16 | |||||||||||
Sponsor Name:Dr. Luis Serra Majem | |||||||||||||
Full Title: Dieta Mediterránea, Ejercicio y Estatinas en el Tratamiento de la Dislipemia | |||||||||||||
Medical condition: Dislipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004758-33 | Sponsor Protocol Number: Rapid-study | Start Date*: 2015-09-08 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Randomized Assessment of patients with clinically suspected Prostate cancer after multiparametric metabolic hybrid Imaging to evaluate its potential clinical Domain: A prospective, randomized, mult... | |||||||||||||
Medical condition: Clinical suspected prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001847-58 | Sponsor Protocol Number: ARD12042 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or in... | |||||||||||||
Medical condition: polycythemia vera, or essential thrombocythemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002525-19 | Sponsor Protocol Number: D5660C00004 | Start Date*: 2016-01-27 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients ... | ||||||||||||||||||
Medical condition: Part A (US ONLY): advanced solid malignancies Part B (NA, EU): Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Restarted) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002718-32 | Sponsor Protocol Number: CanStem43L | Start Date*: 2017-04-04 | |||||||||||
Sponsor Name:Boston Biomedical, Inc. | |||||||||||||
Full Title: A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Ca... | |||||||||||||
Medical condition: Histologically or cytologically confirmed recurrent, locally advanced, or metastatic non-squamous non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002403-18 | Sponsor Protocol Number: ET12-034 | Start Date*: 2013-01-17 | |||||||||||
Sponsor Name:Centre Léon Berard | |||||||||||||
Full Title: PIK-ORL: A Phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients with metastatic head and neck cancer recurrent or progressive under platin and cetuximab-based chemotherapy | |||||||||||||
Medical condition: Patients with metastatic or relapsed head and neck cancer and documented progression or relapse after platin and cetuximab-based chemotherapy (combination or sequential treatment) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006647-45 | Sponsor Protocol Number: D1060C00001 | Start Date*: 2009-05-14 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary ... | ||||||||||||||||||
Medical condition: Myeloproliferative disorders including Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000881-39 | Sponsor Protocol Number: P/2019/418 | Start Date*: 2019-12-10 |
Sponsor Name:CHU de Besançon | ||
Full Title: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers | ||
Medical condition: cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
